Evidence map›Paper›PMID 34527580›Full record

ArticleFrontiers in oncology2021

High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis.

Philippa Li, Ji Yuan, Fahad Shabbir Ahmed, Austin McHenry, Kai Fu, Guohua Yu, Hongxia Cheng, Mina L Xu, David L Rimm, Zenggang Pan

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Iranian journal of basic medical sciences · 2025
    Article
  5. Article
  6. Macrophages and angiogenesis in human lymphomas.Clinical and experimental medicine · 2024
    Review
  7. Article
  8. Article
  9. High M2/M1 Macrophage Ratio Observed in Nasal Polyps Formed in Allergic Fungal Rhinosinusitis.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Philippa LiDepartment of Pathology, Yale University School of Medicine, New Haven, CT, United States.
Ji YuanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
Fahad Shabbir AhmedDepartment of Pathology, Yale University School of Medicine, New Haven, CT, United States.
Austin McHenryDepartment of Pathology, Yale University School of Medicine, New Haven, CT, United States.
Kai FuDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, United States.
Guohua YuDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, United States.
Hongxia ChengDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, United States.
Mina L XuDepartment of Pathology, Yale University School of Medicine, New Haven, CT, United States.
David L RimmDepartment of Pathology, Yale University School of Medicine, New Haven, CT, United States.
Zenggang PanDepartment of Pathology, Yale University School of Medicine, New Haven, CT, United States.
Yale University · USMayo Clinic in Arizona · USShandong Provincial Hospital · CNUniversity of Nebraska Medical Center · USWayne State University · USYuhuangding Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLymphoma-associated macrophages (LAMs) are key components in the lymphoma microenvironment, which may impact disease progression and response to therapy. There are two major subtypes of LAMs, CD68+ M1 and CD163+ M2. M2 LAMs can be transformed from M1 LAMs, particularly in certain diffuse large B-cell lymphomas (DLBCL). While mantle cell lymphoma (MCL) is well-known to contain frequent epithelioid macrophages, LAM characterization within MCL has not been fully described. Herein we evaluate the immunophenotypic subclassification, the expression of immune checkpoint molecule PD-L1, and the prognostic impact of LAMs in MCL. MATERIALS AND

methodsA total of 82 MCL cases were collected and a tissue microarray block was constructed. Immunohistochemical staining was performed using CD68 and CD163, and the positive cells were recorded manually in four representative 400× fields for each case. Multiplexed quantitative immunofluorescence assays were carried out to determine PD-L1 expression on CD68+ M1 LAMs and CD163+ M2 LAMs. In addition, we assessed Ki67 proliferation rate of MCL by an automated method using the QuPath digital imaging analysis. The cut-off points of optimal separation of overall survival (OS) were analyzed using the X-Tile software, the SPSS version 26 was used to construct survival curves, and the log-rank test was performed to calculate the

resultsMCL had a much higher count of M1 LAMs than M2 LAMs with a CD68:CD163 ratio of 3:1. Both M1 and M2 LAMs were increased in MCL cases with high Ki67 proliferation rates (>30%), in contrast to those with low Ki67 (<30%). Increased number of M1 or M2 LAMs in MCL was associated with an inferior OS. Moreover, high expression of PD-L1 on M1 LAMs had a slightly better OS than the cases with low PD-L1 expression, whereas low expression of PD-L1 on M2 LAMs had a slightly improved OS, although both were not statistically significant.

conclusionsIn contrast to DLBCL, MCL had a significantly lower rate of M1 to M2 polarization, and the high levels of M1 and M2 LAMs were associated with poor OS. Furthermore, differential PD-L1 expressions on LAMs may partially explain the different functions of tumor-suppressing or tumor-promoting of M1 and M2 LAMs, respectively.

Indexed as

lymphoma associated macrophagelymphoma microenvironmentmantle cell lymphomaPD-L1quantitative immunofluorescence analysis

Identifiers

PMID34527580
PMCPMC8435777
OpenAlexW3198627542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.